
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

SCHEDULE 13D

**UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 5)***

Selecta Biosciences, Inc.

(Name of Issuer)

**Common Stock, \$0.0001 par value per share
(Title of Class of Securities)**

**816212104
(CUSIP Number)**

**E. Peter Strand
Michael K. Bradshaw, Jr.
Nelson Mullins Riley & Scarborough LLP
101 Constitution Avenue NW, Suite 900
Washington, DC 20001
Tel: (202) 689-2800
Fax: (202) 689-2860**

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

**October 6, 2020
(Date of Event which Requires Filing of this Statement)**

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are sent.

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1.	Names of Reporting Persons. Timothy A. Springer	
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) <input type="checkbox"/> (b) <input type="checkbox"/>	
3.	SEC Use Only	
4.	Source of Funds (See Instructions) PF	
5.	Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)	
6.	Citizenship or Place of Organization United States	
Number of Shares Beneficially Owned by Each Reporting Person With	7.	Sole Voting Power 18,404,586 shares
	8.	Shared Voting Power 0 shares
	9.	Sole Dispositive Power 18,404,586 shares
	10.	Shared Dispositive Power 0 shares
11.	Aggregate Amount Beneficially Owned by Each Reporting Person 18,404,586 shares	
12.	Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)	
13.	Percent of Class Represented by Amount in Row (11) 17.2%	
14.	Type of Reporting Person (See Instructions) IN, OO	

1.	Names of Reporting Persons. TAS Partners LLC	
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) <input type="checkbox"/> (b) <input type="checkbox"/>	
3.	SEC Use Only	
4.	Source of Funds (See Instructions) OO	
5.	Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)	
6.	Citizenship or Place of Organization Delaware	
Number of Shares Beneficially Owned by Each Reporting Person With	7.	Sole Voting Power 10,919,003 shares
	8.	Shared Voting Power 0 shares
	9.	Sole Dispositive Power 10,919,003 shares
	10.	Shared Dispositive Power 0 shares
11.	Aggregate Amount Beneficially Owned by Each Reporting Person 10,919,003 shares	
12.	Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)	
13.	Percent of Class Represented by Amount in Row (11) 10.2%	
14.	Type of Reporting Person (See Instructions) OO	

1.	Names of Reporting Persons. Chafen Lu	
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) <input type="checkbox"/> (b) <input type="checkbox"/>	
3.	SEC Use Only	
4.	Source of Funds (See Instructions) PF	
5.	Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)	
6.	Citizenship or Place of Organization United States	
Number of Shares Beneficially Owned by Each Reporting Person With	7.	Sole Voting Power 86,418 shares
	8.	Shared Voting Power 0 shares
	9.	Sole Dispositive Power 86,418 shares
	10.	Shared Dispositive Power 0 shares
11.	Aggregate Amount Beneficially Owned by Each Reporting Person 86,418 shares	
12.	Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)	
13.	Percent of Class Represented by Amount in Row (11) 0.1%	
14.	Type of Reporting Person (See Instructions) IN, OO	

This Amendment No. 5 to the statement on Schedule 13D (this “Statement”) with respect to the shares of common stock, par value \$0.0001 per share (the “Shares”), of Selecta Biosciences, Inc., a Delaware corporation (the “Issuer”), originally filed by Timothy A. Springer (“Dr. Springer”), TAS Partners LLC (“TAS”), Chafen Lu (“Dr. Lu” and, collectively, the “Reporting Persons”) and Leukon Investments, LP (“Leukon”) filed on March 27, 2019, as amended by Amendment No. 1 to the statement on Schedule 13D filed on August 23, 2019, Amendment No. 2 to the statement on Schedule 13D filed on September 16, 2019, Amendment No. 3 to the statement on Schedule 13D filed on December 17, 2019 and Amendment No. 4 to the statement on Schedule 13D filed on January 2, 2020 (such statement and amendments, as further amended herein, the “Schedule 13D”) amends the Schedule 13D as set forth below.

All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule 13D. Except as specifically amended by this Amendment No. 5, items in the Schedule 13D are unchanged.

Item 3. Source and Amount of Funds or Other Consideration.

Item 3 of the Schedule 13D is hereby amended to be supplemented by the following:

On October 6, 2020, TAS purchased 2,000,000 Shares on the open market at a weighted average price of \$1.6829 per share for an aggregate purchase price of approximately \$3,365,800 (excluding commissions). TAS drew from its investment capital for such acquisition.

On October 7, 2020, TAS purchased 654,953 Shares on the open market at a weighted average price of \$1.6468 per share for an aggregate purchase price of approximately \$1,078,577 (excluding commissions). TAS drew from its investment capital for such acquisition.

On October 8, 2020, TAS purchased 530,441 Shares on the open market at a weighted average price of \$1.88683 per share for an aggregate purchase price of approximately \$1,000,852 (excluding commissions). TAS drew from its investment capital for such acquisition.

On October 9, 2020, TAS purchased 276,703 Shares on the open market at a weighted average price of \$1.99659 per share for an aggregate purchase price of approximately \$552,462 (excluding commissions). TAS drew from its investment capital for such acquisition.

Dr. Springer is the beneficial owner of an additional 46,410 Shares underlying options, of which 6,410 were granted on June 16, 2017 with an exercise price of \$17.47 per share, 10,000 were granted on June 22, 2018 with an exercise price of \$12.75 per share, 10,000 were granted on June 14, 2019 with an exercise price of \$2.10 per share and 20,000 were granted on June 19, 2020 with an exercise price of \$3.00 per share (collectively, the “Options”), 26,410 of which were fully exercisable as of October 9, 2020. The Options were awarded as compensation for Dr. Springer’s service as a member of the board of directors for the Issuer and Dr. Springer paid no consideration for the Options. The Options each have a term of ten years from the respective date of grant. Dr. Springer has not exercised any portion of any of the Options as of the date hereof.

Item 5. Interest in Securities of the Issuer.

Item 5 of Schedule 13D is hereby amended and restated in full as follows:

The information set forth under Item 3 and the cover page of the Schedule 13D is incorporated herein by reference into this Item 5.

(a) The percentages of beneficial ownership reported in this Item 5, and on each Reporting Person's cover page to this Statement, are based on a total of 107,143,410 Shares issued and outstanding as of July 31, 2020, as reported on the Issuer's Quarterly Report on Form 10-Q, dated August 6, 2020. All of the Share numbers reported below, and on each Reporting Person's cover page to this Statement, are as of October 9, 2019.

The Reporting Persons, in the aggregate, beneficially own 18,404,586 Shares, representing approximately 17.2% of such class of securities.

Dr. Springer is the beneficial owner of a total of 18,404,586 Shares, representing approximately 17.2% of the outstanding Shares and consisting of (i) 7,293,625 Shares held directly, (ii) 79,130 Shares underlying warrants exercisable within 60 days of October 9, 2020 and held directly, (iii) 26,410 Shares issuable upon exercise of outstanding options within 60 days of October 9, 2020 and held directly, (iv) 8,948,560 Shares held by TAS, (v) 1,970,443 Shares underlying warrants exercisable within 60 days of October 9, 2020 held by TAS, and (vi) 86,418 Shares held by Dr. Lu.

TAS is the beneficial owner of a total of 10,919,003 Shares, representing approximately 10.2% of the outstanding Shares and consisting of (i) 8,948,560 Shares and (ii) 1,970,443 Shares underlying warrants exercisable within 60 days of October 9, 2020. TAS holds all such Shares directly. Dr. Springer is the sole managing member of TAS.

Dr. Lu is the beneficial owner of a total of 86,418 Shares, representing approximately 0.1% of the outstanding Shares. Dr. Lu holds all such Shares directly. Dr. Lu is the spouse of Dr. Springer.

(b) Dr. Springer exercises sole voting and dispositive power over the Shares held by him directly and the Shares held by TAS. Dr. Springer disclaims beneficial ownership of the Shares held by TAS, except to the extent of his pecuniary interest therein. Dr. Lu exercises sole voting and dispositive power over the Shares held by her directly.

(c) The Reporting Persons have not engaged in any transactions with respect to the Shares during the 60 days before the date of this filing, except as described herein and in Item 3 of Schedule 13D.

(d) No person other than the Reporting Persons is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares.

(e) Not applicable.

[signature page follows]

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: October 15, 2020

/s/ Timothy A. Springer

Timothy A Springer

/s/ Chafen Lu

Chafen Lu

TAS Partners LLC

By: /s/ Timothy A. Springer

Name: Timothy A. Springer

Title: Manager
